National and Kapodistrian University of Athens
Διερεύνηση του μοριακού μονοπατιού και της κλινικής συσχέτισης του αυξητικού παράγοντα της ινσουλίνης τύπου Ι σε ασθενείς με προχωρημένο μη μικροκυτταρικό καρκίνο πνεύμονα
Abstract
dc:descriptionInsulin-like growth factor 1(IGF-1) signaling pathway has been suggested as an important oncogenic mediator in various malignancies, including lung cancer. In this study, we aimed to evaluate serum levels of IGF-1, IGF-2 and IGF Binding Protein 3 (IGF-BP3) before and after chemotherapy or chemoradiotherapy treatment in patients with locally advanced/metastatic non-small cell lung cancer (NSCLC) and their potential correlation with response to therapy and patient survival. Methods: Seventy-three patients with stage III/IV NSCLC were included in the study. Expression of IGF1, IGF2, and IGFBP3 was evaluated in peripheral blood samples in two separate time points, at baseline and 3 months post treatment. Analysis and quantification of circulating levels of IGF-1, IGF-2, IGF-BP3 were performed by total ELISA technique. IGF-1/IGF-BP3 ratio is considered an indicator of IGF-1bioavailability. Results: In univariate analysis, the median value of IGF-1 after treatment (130.80 vs 98.00 ng/ml, p=0.087), and the median ratio of IGF-1/IGF-BP3 (0.01044 vs 0.00678,p=0.056) were higher in responders. Further analysis of the variation of each biomarker before and after treatment showed that the median value of IGF-1 was decreased after treatment in the total population (125.82 from 133.4 ng/ml, p=0.087), albeit no difference was found between subgroups. In addition, the median value of IGF-1/IGF-BP3 ratio was found to be lower after treatment in the total population (0.01006 from 0.01252, p=0.011). Importantly, the post-treatment value of the ratio was significantly reduced in responders (0.01044 from 0.01255, p=0.02). No correlation was found between variation in biomarker values, patient OS and PFS. Conclusions: In a cohort of patients with stage III/IV NSCLC treated with chemotherapy or chemoradiotherapy, reduction of IGF-1/IGF-BP3 ratio, which is anindicator of IGF-1 bioavailability, was statistically significant in patients that responded to treatment. If validated in larger cohorts, our results support the use ofIGF-1/IGFBP3 as a predictive tool for response to chemotherapy in NSCLC.
Degree
thesis:*- Grantor dc:publisher
- National and Kapodistrian University of Athens
- Year dc:date
- 2019
Author and committee
dc:creator, dc:contributor.*- Authors dc:creator
-
- Kotsantis, Ioannis
- Κωτσαντής, Ιωάννης
Subjects
dc:subject × 12- Αυξητικός παράγοντας ινσουλίνης τύπου ένα (1)
- Αυξητικός παράγοντας ινσουλίνης τύπου δύο (2)
- Μη μικροκυτταρικός καρκίνος πνεύμονα
- Χημειοθεραπεία
- Insulin-like growth factor 1(IGF-1)
- Insulin-like growth factor 2 (IGF-2)
- NSCLC
- Chemotherapy
- Ιατρική και Επιστήμες Υγείας
- Επιστήμες Υγείας
- Medical and Health Sciences
- Health Sciences
Rights
- Language dc:language
- gre
Identifiers
dc:identifier.*- Identifier
- 10.12681/eadd/46637